Ono Pharmaceutical Co Ltd (Ono Pharmaceutical) is a Japan-based company engaged in the manufacture, purchase, and sale of prescription medicines and diagnostic reagents. The company operates as a single reportable segment—its Pharmaceutical business, which encompasses research and development, manufacturing, procurement, and commercial sales activities.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Ono Pharmaceutical concentrates its R&D on delivering original, breakthrough medicines, prioritizing oncology, immunology, neurology, and specialty fields with significant unmet medical needs. The company seeks to boost drug-discovery competitiveness by applying deep disease expertise in these domains. It pursues innovative therapies through open innovation and translational research, partnering worldwide with research institutes and bioventures. Ono also makes targeted investments in novel drug targets and advanced technologies to strengthen R&D capabilities. Its R&D structure includes the Oncology Research Center, Immunology Research Center, Neurology Research Center, and Specialty Research Center. Each center addresses distinct discovery goals: Oncology works on new anti-cancer agents; Immunology advances tumor immunology and treatments for autoimmunity/allergy; Neurology develops therapies for neurodegenerative disease, psychiatric conditions, and chronic pain; and Specialty focuses on medicines for diseases with high unmet need. Discovery Research Partnership and Business Development teams work with these centers to run collaborative research and establish drug-discovery alliances. Ono maintains around 300 active research and discovery collaborations in Japan and abroad. Its development pipeline spans multiple stages, emphasizing oncology and additional therapeutic areas. Key pipeline assets include Opdivo, an anti–PD-1 antibody for hepatocellular carcinoma, MSI-H/dMMR colorectal cancer, and neoadjuvant use in lung and bladder cancers. Birafutobi targets BRAF mutation–positive colorectal cancer, and QINLOCK is positioned for second-line gastrointestinal stromal tumors. Other candidates such as ONO-4578 and ONO-4482 are being developed for gastric cancer and malignant melanoma. In FY2026, the company spent JPY147,043 million on its R&D activities, which, as a percentage of revenue, stood at 28.5% and declined 1.8% YoY.